Violation Tracker Individual Record

Company: 
Jazz Pharmaceuticals Inc.
Current Parent Company: 
Jazz Pharmaceuticals
Penalty: 
$20,000,000
Year: 
2007
Date: 
July 13, 2007
Offense Group: 
healthcare-related offenses
Primary Offense: 
off-label or unapproved promotion of medical products
Secondary Offense: 
False Claims Act and related
Violation Description: 

Jazz Pharmaceuticals, Inc. agreed to pay $20 million in penalties and victim compensation to resolve parallel criminal and civil investigations relating to the illegal marketing practices of its wholly-owned subsidiary Orphan Medical, Inc. Jazz was offered a non-prosecution agreement while Orphan pleaded guilty to felony misbranding, in violation of the Food, Drug, and Cosmetic Act in connection with its illegal promotion of the prescription medication Xyrem.

Level of Government: 
federal
Action Type: 
agency action
Agency: 
U.S. Attorney-Eastern District of New York
Civil or Criminal Case: 
civil and criminal
Prosecution Agreement: 
plea & non-prosecution agreement
HQ Country of Parent: 
Ireland
Ownership Structure of Parent: 
publicly traded
Major Industry of Parent: 
pharmaceuticals
Specific Industry of Parent: 
pharmaceuticals
Source Notes: 
If an online information source is not working, check the Violation Tracker Data Sources page for an updated link.
Parent company note: 
Parent-subsidiary relationship is current as of the most recent revision listed in the Update Log.